$CURR CEO of CURE Pharmaceutical. “Building on t
Post# of 40271
CURE has granted Vanguard rights to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced supercritical fluid extraction technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has reserved all rights to applying these methods in oral thin film.
"CURE is a leader in cannabinoid drug delivery innovation, and this license and collaboration agreement will give our customers peace of mind when selecting our extraction solutions," said Matthew Anderson, CEO of Vanguard Scientific. "Working with CURE, we intend to further our traction in the marketplace by jointly pursuing a focused patenting strategy in order to offer its clients a broader range of protected and defensible separation capabilities."